Review Article

, Volume: 12( 12)

• View PDF
• Download PDF

Pancreatic Cancer: A Review

*Correspondence:

Chandraman k , Department of Pharmaceutics, Bharat Technology, Uluberia, Howrah, India, Tel: 7797923218; E-mail: sirwal0711@gmail.com

Abstract

The incidence of pancreatic cancer has been increasing while its 5-year survival rate has not changed in decades. Pancreatic cancer is associated with a high mortality rate and is one of the top 5 causes of death from cancer. The burden of pancreatic disorders is expected to increase over time. Alcohol continues to be the single most important risk factor for chronic pancreatitis. Smoking is an independent risk factor for acute and chronic pancreatitis, and its effects could synergize with those of alcohol. Significant risk factors for pancreatic cancer include smoking and non-O blood groups. Therefore, these review discuss the different types of pancreatic cancer that usually occurs along with the different phase. It also discusses the sign and symptoms of respective cancer and treatment.

Keywords

Pancreatic malignancy; Neuroendocrine; Pancreatic tissue; Adenocarcinoma

Introduction

Pancreatic disease begins in the tissue of pancreas-a glandular organ in the belly that lies behind the lower part of the stomach start to increase crazy and structure a mass [1-5]. These dangerous cells can damage different parts of the body. Pancreatic malignancy may go undetected until it's progressed.

Pancreatic malignancy regularly has a rare guess, and cannot be diagnosed at the early stage. Pancreatic disease regularly spreads quickly and is at times identified in the first phase, which is the main reason why it is a source of growth passing. Signs and manifestations may not be observed until pancreatic malignancy is entirely cutting-edge and finish surgical evacuation is not conceivable. When side effects happen, diagnosing pancreatic growth is typically moderately clear. Sadly, a cure is seldom conceivable by then.

There are various types of pancreatic malignancy. The most commonly recognized is, pancreatic adenocarcinoma found in about 85% of cases, and the expression "pancreatic disease" is in some cases used to suggest the sort. These adenocarcinomas initiates in the inner parts of the pancreas which makes digestive chemicals. Some different types of diseases, which all things considered speak about most of the non-adenocarcinomas, can emerge in the same manner from these cells. 1% to 2% of cases of pancreatic growth are neuroendocrine tumors, which emerge from the hormone-creating cells of the pancreatic tissue. These are by and large less dominant than pancreatic adenocarcinoma [6-19].

Types

Pancreatic growth is ordered by a part of the pancreatic tissue is influenced: the region that makes the digestive substances (exocrine) or the region that makes the insulin and different hormones (endocrine). Both assembly happen basically (however not completely) in cases more than 40, and are quite more basic in men, yet some uncommon sub-sorts mostly happen in women or children [20-24].

Exocrine pancreatic cancer

Even though the fact that there are a few distinct sorts of exocrine pancreatic disease, 95% of cases are because of pancreatic adenocarcinoma. Different less regular exocrine pancreatic growths include:

• Carcinoma of Adenosquamous

• Carcinoma of Squamous cell

• Carcinoma of Goliath cell

• Carcinoma of Acinar cell

• Little cell carcinoma

The exocrine pancreas makes around 95% of the total pancreas, so it is common that most pancreatic growths emerge here [25-34].

Endocrine pancreatic cancer

• Various cells of the pancreas make hormones that are discharged straightforwardly into the circulation system (endocrine framework). Harmful tumors emerging from these phones are named as pancreatic neuroendocrine tumors or islet tumor cell.

• Endocrine pancreatic growths are unprecedented, and are named by kind of hormone delivered:

• Insulinomas (which is from an insulin-making cells)

• Glucagonomas (which is from a glucagon-conveying cells)

• Somatostatinomas (which is from a somatostatin-generation cells)

• Gastrinomas (which is from a gastrin-conveying cells)

• VIPomas (which is from vasoactive intestinal peptide-generation cell)

Where some pancreatic islet cell tumors don't emit hormones and are called as non-discharging pancreatic islet tumors [35-49].

Signs and Symptoms

Indications of pancreatic growth include:

• Jaundice (yellowing the skin and white part of the eyes)

• Upper or center guts and back ache (may be more terrible around evening time)

• Unexplained weight loss (loss of hankering, poor assimilation)

• Constipation

• Fatigue

• Depression [50-54]

Risk Factors

• Age, sexual orientation, and ethnicity

• Cigarette smoking

• Obesity

• Chronic pancreatitis (irritation in the pancreas)

• Inherited conditions (counting genetic pancreatitis)

• Familial pancreatic tumor disorders

• Long-standing diabetes [55-59]

Diagnosis

Diagnosing pancreatic growth typically happens when somebody goes to the specialist in the wake of encountering weeks or months of manifestations.

• CT check (processed tomography)

• MRI (attractive reverberation imaging)

• Endoscopic ultrasound (EUS)

• Laparoscopy (surgical methodology to take a gander at organs)

• Endoscopic retrograde cholangiopancreatography (ERCP)

• Percutaneous Tran’s hepatic cholangiography (PTC; methodology used to X-beam liver and bile pipes)

• Biopsy (evacuation of tissue to view it under a magnifying lens) Positron outflow tomography (PET sweep) fine needle goal (FNA) [60-64]

Stages/ Phases of Pancreatic Cancer

The method used to identify if the cancer has distributed within the pancreas or to other regions of the body is called staging. The data gathered from the staging method determines the phase of the disease. It is important to know the stage of the disease in order to plan the treatment. The results of some of the tests used to diagnose pancreatic cancer are often used for determining stage of the disease.

Phase 0 (carcinoma in situ)

In phase 0, abnormal cells are found in the coating of pancreas. These strange cells may get to be tumor and spread into close-by ordinary tissue. Phase 0 is further called carcinoma in situ [65-69].

Phase 1

• Pancreatic tumor. In phase IA, the tumor is of 2 cm or littler. In phase IB, the tumor is bigger than 2 cm

• In phase I, tumor has framed and is identified in the pancreas as it were. Phase I is partitioned into phase IA and phase IB, taking into account the measure of the tumor cell.

• Phase IA: The tumor is of 2 cm or littler.

• Phase IB: The tumor is bigger than 2 cm.

Phase II

• In phase II, disease may have spread to adjacent tissues and organs, and may have also spread to lymph hubs close to the pancreas. Phase II is partitioned into phase IIA and phase IIB, in light of where the growth has spread.

• Phage IIA: Cancer has distributed to the adjacent tissue and an organ yet has not spread to close-by lymph hubs.

• Phage IIA pancreatic malignancy: Growth has spread to close-by tissue and organs however have not spread to adjacent lymph hubs.

• Phage IIB: Cancer has distributed to adjacent lymph hubs and may have distributed to close-by tissues and organs.

• Phage IIB pancreatic malignancy: Growth has distributed to close-by lymph hubs and may have also spread to close-by tissues and organs [65-70].

Phase III

• Phase III pancreatic malignancy: Growth has distributed to the real veins close to pancreas. These incorporate the predominant mesenteric course, celiac hub, regular hepatic corridor, and entrance vein. Disease may have spread to adjacent lymph hubs.

• In phase III, malignancy has distributed to the significant veins close to the pancreas and may have distributed to close-by lymph hubs [71-74].

Phase IV

• Phase IV pancreatic harm: Infection may be of any size and has been spread to the distant organs, for instance, the lungs, the liver, and the peritoneal discouragement (the gap in the midsection that accommodates the inner parts, like stomach, and liver). Development may similarly have distributed to tissues and organs near to the pancreas or to the lymph center points.

• In phase IV, harm might be of any size and has spread to such an extent that it is too difficult to reach organs, for instance, the liver, lung, and peritoneal gloom. It may have been furthermore spread to the organs and tissues near to the pancreas or to the lymph centers [75-81].

Treatment

Pancreatic growth is extremely hard to control. Be that as it may, in the event that it is analyzed early and the tumor hasn't spread past the pancreas, it can be dealt with utilizing different medicines, including surgery, chemotherapy, and radiation treatment. Chemotherapy utilizes medications to treat tumor, while radiation treatment utilizes X-beams or different sorts of radiation to execute disease cells. Surgery can be utilized to expel a tumor or to treat manifestations of pancreatic malignancy. This offers the best result for pancreatic malignancy. The surgery is known as pancreaticoduodenectomy, and is named after Dr. George Hoyt Whipple, the specialist who spearheaded it. In the event that conceivable, the specialist evacuates the threatening tumor, leaving however much of the ordinary pancreas as could be expected to permit proceeded with pancreatic capacity. Less regularly, the whole pancreas must be expelled. On the off chance that a patient experiences an aggregate pancreatectomy, a deep rooted regimen of substitution catalysts and hormones, including insulin, must be managed [82-85].

Phase I and II of pancreatic cancer

The treatment of phase I and phase II pancreatic disease may involve the following:

• Surgery.

• Surgery took after by chemotherapy.

• Surgery took after by chemo radiation.

• A clinical test of mix chemotherapy.

• A clinical test of chemotherapy and concentrated on treatment, with or without chemo radiation.

• A clinical test of chemotherapy or radiation treatment before surgery [86-89].

Phase III of pancreatic cancer

Treatment of phase III pancreatic malignancy may involve the following:

• Palliative surgery or stent position to evade blocked extents in channels or the little digestive tract.

• Chemotherapy took after chemo radiation.

• Chemo radiation took after chemotherapy.

• Chemotherapy with or without centered treatment.

• A clinical test of new anticancer therapy along with chemotherapy or chemo radiation.

• A clinical test of radiation therapy given amid surgery or interior radiation therapy [90-92].

Phage IV pancreatic cancer

• The treatment of stage IV pancreatic cancer may include the following:

• Palliative treatments to relieve pain, such as nerve blocks, and other supportive care.

• Palliative surgery or stent placement to bypass blocked areas in ducts or the small intestine.

• Chemotherapy with or without targeted therapy.

• Clinical trials of new anticancer specialists with or without chemotherapy [93-95].

Conclusion

Pancreas is a gland which secretes many enzymes and hormones which are very essential for the process of digestion. Any damage to it may lead to serious complications and may alter the whole physiology of the body pancreatic cancer is a disease which is very difficult to diagnose in the initial stage, so slight pain in the upper abdomen which indicates the location of the organ should to notified to doctor and future diagnosis process should be carried out. One should stay away from cigarette smoking, alcohol, limit exposure to carcinogenic chemicals in work places, and take healthy diet. Diet always plays a major role, so maintaining a healthy and nutrias diet can keep us away from many deadly diseases. Chemotherapy and radiology along with self-confidence are necessary for the treatment of the disease [96-99].

References

1. Feghali A, Amankwah K, Goldenberg A, et al. Utilization of Intravascular Ultrasound to Assess Vascular Invasion in Pancreatic Cancer Post Chemoradiation Therapy. J Vasc Med Surg. 2016;4(3):275.
2. Shibata M, Matsui T, Ishiwatari H, et al. A Case of Inconspicuous Pancreatic Cancer with Invasion of the Celiac Axis and Superior Mesenteric Artery. J Clin Case Rep. 2016;6(5):1-3.
3. Principe M, Cappello P, Novelli F. Blockade of Surface Alpha-Enolase (ENO1) as a Novel Immunotherapeutic Approach in Pancreatic Cancer. Chemo Open Access. 2016;6(5):1-3.
4. Patel GK, Patton MC, Singh S, et al. Pancreatic Cancer Exosomes Shedding Off for a Meaningful Journey. Pancreat Disord Ther. 2016;6(2):148.
5. Cuttler JM, Garzon P, Mitchel REJ, et al. Adjuvant Therapy for Resected Exocrine Pancreatic Cancer by Half-Body Low-Dose Irradiation. J Cancer Clin Trials. 2016;1(2):1-6.
6. Latief M, Dar WR, Qayoom O, et al. An Unusual Presentation of Pancreatic Cancer. J Gen Pract. 2016:4(1);1-3.
7. Casadei R, Bogoni S, Ricci C, et al. Pancreatic Cancer Resection and Incidental Congenital Anomaly of the Inferior Vena Cava. Pancreat Disord Ther. 2016;6(1):1-2.
8. Ali S, Dubaybo H, Brand RE, et al. Differential Expression of Micrornas in Tissues and Plasma Co-exists as a Biomarker for Pancreatic Cancer. J Cancer Sci Ther. 2015;7(11):336-46.
9. Vescarelli E, Ceccarelli S, Angeloni A. Role of Fibroblast Growth Factor Receptor 2 in Pancreatic Cancer Potential Target for New Therapeutic Approach? Pancreat Disord Ther. 2015;5(3):164.
10. Mori H, Yamada Y, Kiyonaga M, et al. Diagnostic Utility of Reduced Radiation Dose Non-Contrast-Enhanced CT with Iterative Reconstruction for Screening in High-Risk Individuals with Pancreatic Cancer an Anthropomorphic Phantom Study. Pancreat Disord Ther. 2015;5(3):1-6.
11. Noro J, Maciel J, Duarte D, et al. Evaluation of New Naphthalimides as Potential Anticancer Agents against Breast Cancer MCF-7, Pancreatic Cancer BxPC-3 and Colon Cancer HCT-15 Cell Lines. Organic Chem Curr Res. 2015;4:(3):1-11.
12. Awasthi N, Schwarz MA, Wang C, et al. Increasing Bioavailability of Cytotoxic Agents through Prolonged Therapy and Addition of Polymechanistic Antiangiogenic Agents Enhances Antitumor Response in Pancreatic Cancer. Biochem Pharmacol (Los Angel). 2015;4(4):177.
13. Shimodaira S, Kobayashi T, Hirabayashi K, et al. Induction of Antigen-Specific Cytotoxic T Lymphocytes by Chemoradiotherapy in Patients Receiving Wilms’ Tumor 1-Targetted Dendritic Cell Vaccinations for Pancreatic Cancer. OMICS J Radiol. 2015;4(4):196.
14. Malhotra L, Ahn DH, Bloomston M. The Pathogenesis, Diagnosis, and Management of Pancreatic Cancer. J Gastrointest Dig Syst. 2015;4(5):295.
15. Ibrahim T, Larsen S, HLindkær Jensen N, et al. BPC2 improves Functional status, Quality of Life and Corrects Biochemical Imbalances as Adjuvant Therapy to FOLFIRINOX Treatment a Case of Advanced Inoperable Pancreatic Cancer. J Clin Case Rep. 2015;5(4):514.
16. Vietsch E, Eijck CH, Wellstein A. Circulating DNA and Micro-RNA in Patients with Pancreatic Cancer. Pancreat Disord Ther. 2015;5(2):156.
17. Patel A, Nagarajan S, Scher E, et al. Early vs. Late Chemoradiation Therapy and the Postoperative Interval to Adjuvant Therapy do not Correspond to Local Recurrence in Resected Pancreatic Cancer. Pancreat Disord Ther. 2015;5(2):151.
18. Maraveyas A, Muazzam IA. Thromboprophylaxis in Pancreatic Cancer Why Isn’t Prime Time Here Compared to Multiple Myeloma? Pancreat Disord Ther. 2015;5(1):137.
19. Maute L, Wicht J, Bergmann L. The Dual PI3K/mTOR Inhibitor NVPBEZ235 Enhances the Antitumoral Activity of Gemcitabine in Human Pancreatic Cancer Cell Lines. J Integr Oncol. 2015;4(1):1-13.
20. Raji Sundararajan. Irreversible Electroporation a New Hope for the Pancreatic Cancer Patients. J Nanomedine Biotherapeutic Discov. 2015;5(1):136.
21. Valenzuela MMA. Antimetabolite Treatment for Pancreatic Cancer. Chemotherapy. 2014;3(3):137.
22. Basso D, Gnatta E, Plebani M. Pancreatic Cancer Fostered Immunosuppression Privileges Tumor Growth and Progression. J Clin Cell Immunol. 2014;5(6):278.
23. Haun RS, Fan CY, Mackintosh SG, et al. CD109 Overexpression in Pancreatic Cancer Identified by Cell-Surface Glycoprotein Capture. J Proteomics Bioinform. 2014;10:S10003.
24. Yadav DK, deLu C, Yadav RK. Vaccine Therapy for Pancreatic Cancer a Battle against Deadly Cancer. J Cancer Sci Ther. 2014;6(8):268-77.
25. Sundararajan R. Nanocurcumin-Based Electrochemotherapy for Pancreatic Cancer The Answer the World is Looking For. J Nanomedine Biotherapeutic Discov. 2014;4(2):131.
26. Liang XY, Li QQ, Zhang ZL, et al. High Mobility Group Box 1 (HMGB1) is Associated with Progression and Poor Prognosis in Pancreatic Cancer. J Gastroint Dig Syst. 2014;4(3):190.
27. Deeb D, Brigolin C, Gao X, et al. Induction of Apoptosis in Pancreatic Cancer Cells by CDDO-Me Involves Repression of Telomerase through Epigenetic Pathways. J Carcinog & Mutagen. 2014;5(3):177.
28. Rudroff C, Richard A, Hilswicht S, et al. The Expression of the Thrombin Receptorsv PAR-3 and PAR-4 is Downregulated in Pancreatic Cancer Cell Lines. Journal of Surgery. 2014;10(1):35-41.
29. Husain K. Pancreatic Cancer Treatment. J Drug Metab Toxicol. 2014;5(1):162.
30. Lo KK, Moore EE, Chin T, et al. Thrombelastography Delineates Hypercoagulability in an Immunocompetent Murine Model of Metastatic Pancreatic Cancer. Pancreat Disord Ther. 2013;3(3):126.
31. Qing-quan C, Feng G, Ze-hao Z, et al. Trypsin-antitrypsin Imbalance in Immune Escape and Clonal Proliferation of Pancreatic Cancer. J Genet Syndr Gene Ther. 2011;4(11):200.
32. Zhang Q, Bhojani MS, Josef EB, et al. Glycogen Synthase Kinase 3β in Pancreatic Cancer and its Implications in Chemotherapy and Radiation Therapy. J Carcinogene Mutagene. 2013;4(3):147.
33. Schuller HM. The Neuro-Psychological Axis of Pancreatic Cancer as a Novel Target for Intervention. Pancreat Disord Ther. 2013;3(3):124.
34. Yamamoto K, Shimada S, Kuramoto M, et al. Prophylactic Strategy for Peritoneal Recurrence after Curative Operation in Pancreatic Cancer. J Cytol Histol. 2013;4(4):185.
35. Zheng D, Chen H, Bartee MY, et al. Myxomaviral Anti-Inflammatory Serpin Reduces Myeloid-Derived Suppressor Cells and Human Pancreatic Cancer Cell Growth in Mice. J Cancer Sci Ther. 2013;5(8):291-99.
36. Berardi R, Mandolesi A, Pellei C, et al. Prognostic Factors in Pancreatic Cancer The Role of Perineural, Vascular and Lymphatic Invasion and of Ca19-9. J Gastroint Dig Syst. 2013;3(3):134.
37. Welsh JL, Du J, Sibenaller ZA, et al. Ascorbate-Induced Autophagy in Pancreatic Cancer. Pancreatic Dis Ther. 2013;3(2):119.
38. Feng X, Cai A, Dong K, et al. Assessing Pancreatic Cancer Risk Associated with Dipeptidyl Peptidase 4 Inhibitors Data Mining of FDA Adverse Event Reporting System (FAERS). J Pharmacovigilance. 2013;1(3):110.
39. Matsushita A, Nakamura Y, Sumiyoshi H, et al. A Pilot Study-Neoadjuvant Chemotherapy with Gemcitabine and S1 in Patients with Resectable and Borderline Resectable Pancreatic Cancer. J Carcinogene Mutagene. 2013;S9:006.
40. Nakamura Y, Matsushita A, Sumiyoshi H, et al. Laparoscopic Pancreatectomy for Pancreatic Cancer. J Carcinogene Mutagene. 2013;S9:004.
41. Yoshimura H, Matsuda Y, Naito Z, et al. In Vivo Bioluminescence Imaging of Pancreatic Cancer Xenografts in NOG Mice. J Carcinogene Mutagene. 2013;S9:003.
42. Matsuda Y, Yoshimura H, Naito Z, et al. The Roles and Molecular Mechanisms of Nestin Expression in Cancer with a focus on pancreatic Cancer. J Carcinogene Mutagene. 2013;S9:002.
43. Dabernat S, Lafitte M, Bedel A, et al. Gene Therapy of Pancreatic Cancer. J Genet Syndr Gene Ther. 2013 4(4):138.
44. Ma J, Xia J, Miele L, et al. Notch Signaling Pathway in Pancreatic Cancer Progression. Pancreat Disord Ther. 2013;3(114):1000114.
45. Costello LC, Franklin RB. A Review of the Current Status and Concept of the Emerging Implications of Zinc and Zinc Transporters in the Development of Pancreatic Cancer. Pancreat Disord Ther. 2013;S4:002.
46. Saxena S, Gandhi A, Lim PW, et al. RAN GTPase and Osteopontin in Pancreatic Cancer. Pancreat Disord Ther. 2013;3(1):113.
47. Mohelnikova-Duchonova B. Pancreatic Cancer Specific Problems of Genetic Profiling. Pancreatic Dis Ther. 2013;3(1):111.
48. Lu QY, Zhang L, Lugea A, et al. Determination of Rottlerin, a Natural Protein Kinases C Inhibitor, in Pancreatic Cancer Cells and Mouse Xenografts by RP-HPLC Method. J Chromatogr Sep Tech. 2013;4(1):100062.
49. Tan Y, Miele L, Sarkar FH, et al. Identifying Biomarkers and Drug Targets Using Systems Biology Approaches for Pancreatic Cancer. Pancreat Disorders Ther. 2012;2(4):1000e128.
50. Mondal U, Henkes N, Patel S, et al. Endoscopic Ultrasound Elastography Current Clinical Use in Pancreas. Pancreas. 2016;45(7):929-33.
51. Strosberg JR, Cheema A, Weber J, et al. Prognostic Validity of the American Joint Committee on Cancer and the European Neuroendocrine Tumors Staging Classifications for Pancreatic Neuroendocrine Tumors. J Clin Oncol. 2011;29(22):3044-9.
52. Hideyo K, Takao O, Takaaki F, et al. Different Hormonal Expression Patterns Between Primary Pancreatic Neuroendocrine Tumors and Metastatic Sites. Pancrease. 2016;45(7):946-52.
53. Arnachellum RP, Cariou M, Nousbaum JB, et al. Pancreatic Adenocarcinoma in the Finistère Area, France, Between 2002 and 2011 (1002 Cases) Population Characteristics, Treatment and Survival. Pancrease. 2016;45(7):953-60.
54. Michael CY, Jake RT, James SH, et al. Preoperative Computerized Tomography and Magnetic Resonance Imaging of the Pancreas Predicts Pancreatic Mass and Functional Outcomes After Total Pancreatectomy and Islet Auto transplant. Pancrease. 2016;45(7):961-6.
55. Elina A, Ioannis C, Antonia MS, et al. Proglucagon-Derived Peptides Do Not Significantly Affect Acute Exocrine Pancreas in Rats. Pancrease. 2016;45(7):967-73.
56. Ashley HD, Andrea M A, Jose MP, et al. Increased Expression of the Glucose Transporter Type 1 Gene Is Associated with Worse Overall Survival in Resected Pancreatic Adenocarcinoma. Pancrease. 2016;45(7): 974-9.
57. Gomercic C, Gelsi E, Van Gysel D, et al. Assessment of D-Dimers for the Early Prediction of Complications in Acute Pancreatitis. Pancreas. 2016;45(7):980-5.
58. Olson SH, Xu Y, Herzog K, et al. Weight Loss, Diabetes, Fatigue, and Depression Preceding Pancreatic Cancer. Pancreas. 2016;45(7):986-91.
59. Siegel R, Naishadham D, Jemal A. Cancer statistics. CA Cancer J Clin. 2013;63(1):11-30.
60. Morris JP, Wang SC, Hebrok M. KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma. Nat Rev Cancer. 2010;10(10):683-95.
61. Bardeesy N, DePinho RA. Pancreatic cancer biology and genetics. Nat Rev Cancer. 2002;2(12):897-909.
62. Klein AP. Identifying people at a high risk of developing pancreatic cancer. Nat Rev Cancer. 2013;13(1):66-74.
63. Wang Z, Li Y, Sarkar FH. Notch signaling proteins legitimate targets for cancer therapy. Curr Protein Pept Sci. 2010;11(6):398-408.
64. Wang Z, Li Y, Banerjee S, et al. Exploitation of the Notch signaling pathway as a novel target for cancer therapy. Anticancer Res. 2008;28(6A):3621-30.
65. Ranganathan P, Weaver KL, Capobianco AJ. Notch signalling in solid tumours a little bit of everything but not all the time. Nat Rev Cancer. 2011;11(5):338-51.
66. Miele L, Miao H, Nickoloff BJ. NOTCH signaling as a novel cancer therapeutic target. Curr Cancer Drug Targets. 2006;6(4):313-23.
67. Radtke F, Raj K. The role of Notch in tumorigenesis oncogene or tumour suppressor? Nat Rev Cancer. 2003;3(10):756-67.
68. Rizzo P, Osipo C, Foreman K, et al. Rational targeting of Notch signaling in cancer. Oncogene. 2008;27(38):5124-31.
69. Miele L. Notch signaling. Clin Cancer Res. 2006;12(4):1074-9.
70. Ristorcelli E, Lombardo D. Targeting Notch signaling in pancreatic cancer. Expert Opin Ther Targets. 2010;14(5):541-52.
71. Mysliwiec P, Boucher MJ. Targeting Notch signaling in pancreatic cancer patients-rationale for new therapy. Adv Med Sci. 2009;54(2):136-42.
72. Büchler P, Gazdhar A, Schubert M, et al. The Notch signaling pathway is related to neurovascular progression of pancreatic cancer. Ann Surg. 2005;242(6):791-800.
73. Miyamoto Y, Maitra A, Ghosh B, et al. Notch mediates TGF alpha-induced changes in epithelial differentiation during pancreatic tumorigenesis. Cancer Cell. 2003;3(6):565-76.
74. Wang Z, Zhang Y, Li Y, et al. Down-regulation of Notch-1 contributes to cell growth inhibition and apoptosis in pancreatic cancer cells. Mol Cancer Ther. 2006;5(3):483-93.
75. Wang Z, Zhang Y, Banerjee S, et al. Inhibition of nuclear factor kappab activity by genistein is mediated via Notch-1 signaling pathway in pancreatic cancer cells. Int J Cancer. 2006;118(8):1930-6.
76. Wang Z, Li Y, Banerjee S, et al. Down-regulation of Notch-1 and Jagged-1 inhibits prostate cancer cell growth, migration and invasion, and induces apoptosis via inactivation of Akt, mTOR, and NF-kappaB signaling pathways. J Cell Biochem. 2010;109(4):726-36.
77. Plentz R, Park JS, Rhim AD, et al. Inhibition of gamma-secretase activity inhibits tumor progression in a mouse model of pancreatic ductal adenocarcinoma. Gastroenterology. 2009;136(5):1741-9.
78. Hanlon L, Avila JL, Demarest RM, et al. Notch1 functions as a tumor suppressor in a model of K-ras-induced pancreatic ductal adenocarcinoma. Cancer Res. 2010;70(11):4280-6.
79. Wang Z, Li Y, Kong D, et al. The role of Notch signaling pathway in epithelial-mesenchymal transition (EMT) during development and tumor aggressiveness. Curr Drug Targets. 2010;11(6):745-51.
80. De Craene B, Berx G. Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer. 2013;13(2):97-110.
81. Rhim AD, Mirek ET, Aiello NM, et al. EMT and dissemination precede pancreatic tumor formation. Cell. 2012;148(1-2):349-61.
82. Leong KG, Niessen K, Kulic I, et al. Jagged1-mediated Notch activation induces epithelial-to-mesenchymal transition through Slug-induced repression of E-cadherin. J Exp Med. 2007;204(12):2935-48.
83. Wang Z, Li Y, Kong D, et al. Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res. 2009;69(6):2400-7.
84. Kang M, Jiang B, Xu B, et al. Delta like ligand 4 induces impaired chemo-drug delivery and enhanced chemoresistance in pancreatic cancer. Cancer Lett. 2013;330(1):11-21.
85. Kabashima-Niibe A, Higuchi H, Takaishi H, et al. Mesenchymal stem cells regulate epithelial-mesenchymal transition and tumor progression of pancreatic cancer cells. Cancer Sci. 2013;104(2):157-64.
86. Güngör C, Zander H, Effenberger KE, et al. Notch signaling activated by replication stress-induced expression of midkine drives epithelial-mesenchymal transition and chemoresistance in pancreatic cancer. Cancer Res. 2011;71(14):5009-19.
87. Bao B, Wang Z, Ali S, et al. Notch-1 induces epithelial-mesenchymal transition consistent with cancer stem cell phenotype in pancreatic cancer cells. Cancer Lett. 2011;307(1):26-36.
88. Nguyen LV, Vanner R, Dirks P, et al. Cancer stem cells an evolving concept. Nat Rev Cancer. 2012;12(2):133-43.
89. Valent P, Bonnet D, De Maria R, et al. Cancer stem cell definitions and terminology: the devil is in the details. Nat Rev Cancer. 2012;12(11):767-75.
90. Hong SP, Wen J, Bang S, et al. CD44-positive cells are responsible for gemcitabine resistance in pancreatic cancer cells. Int J Cancer. 2009;125(10):2323-31.
91. Wang Z, Li Y, Banerjee S, et al. Emerging role of Notch in stem cells and cancer. Cancer Lett. 2009;279(1):8-12.
92. Ji Q, Hao X, Zhang M, et al. MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. PLoS One. 2009;4(8):e6816.
93. Kasinski AL, Slack FJ. Epigenetics and genetics. MicroRNAs en route to the clinic progress in validating and targeting microRNAs for cancer therapy. Nat Rev Cancer. 2011;11(12):849-64.
94. Ryan BM, Robles AI, Harris CC. Genetic variation in microRNA networks the implications for cancer research. Nat Rev Cancer. 2010;10(6):389-402.
95. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006;6(11):857-66.
96. Brabletz S, Bajdak K, Meidhof S, et al. The ZEB1/miR-200 feedback loop controls Notch signalling in cancer cells. EMBO J. 2011;30(4):770-82.
97. Wang Z, Li Y, Ahmad A, et al. Targeting Notch signaling pathway to overcome drug resistance for cancer therapy. Biochim Biophys Acta. 2010;1806(2):258-67.
98. Espinoza I, Miele L. Notch inhibitors for cancer treatment. Pharmacol Ther. 2013;139(2):95-110.
99. Palagani V, El Khatib M, Kossatz U, et al. Epithelial mesenchymal transition and pancreatic tumor initiating CD44+/EpCAM+ cells are inhibited by γ-secretase inhibitor IX. PLoS One. 2012;7(10):e46514.